- United Immunity has also been awarded approximately ¥2.8 billion in grant funding from the Japan Agency for Medical Research and Development (AMED) under its Strengthening Program for the Pharmaceutical Startup Ecosystem.
- Together, the company will have access to up to ¥5.0 billion (approximately US$38 million) in total development funding.
- The company will leverage these financial resources to advance the global clinical development of UI-102 and accelerate the development of its innovative in vivo CAR-macrophage immunotherapy for the treatment of cancer.
TOKYO, Japan, September 24, 2026 / Biotech Newswire / -- United Immunity Co., Ltd., a clinical stage biotechnology company, today announced that it has raised a total of ¥2.2 billion in private financing, comprising ¥1.8 billion through a third-party allotment of new shares and ¥0.4 billion through debt financing.
In addition, the company’s project, “Development of in vivo CAR-Macrophage Therapy for Refractory Solid Tumors,” has been selected for the Strengthening Program for Pharmaceutical Startup Ecosystem (V-eco) of the Japan Agency for Medical Research and Development (AMED).
By combining the ¥2.2 billion in private financing raised in this round with up to approximately ¥2.8 billion in public grant funding, the company expects to have access to up to ¥5.0 billion in total development funding to accelerate research and clinical development of its lead program UI-102 and in vivo macrophage engineering programs for the treatment of solid tumors and fibrotic diseases.
The company will also consider additional financing, as needed, to accelerate and expand new research and development programs in therapeutic areas beyond oncology.
“This financing will enable us to strengthen our foundation as a drug-discovery company to operate globally and to significantly enhance our R&D capabilities to bring new treatment options to patients" said Masato Kishida CEO. "We are deeply grateful to the corporations, investors, financial institutions, AMED, and all other stakeholders who have supported us. United Immunity will continue working to deliver to patients around the world innovative in vivo immunotherapies originating in Japan and born from the convergence of immunology and nanoparticle technology".
Investors and financing providers in this round (in no particular order): ITOCHU Corporation; Ono Venture Investment, Inc. (Ono Pharmaceutical CVC); Ricoh Biomedical Startup Investment Limited Partnership (Ricoh CVC); Saisei Bioventures L.P.; UTEC 5 Investment Limited Partnership (The University of Tokyo Edge Capital Partners); Mizuho Life Science No. 1 Investment Limited Partnership (Mizuho Capital); MUFG Life Science No. 2 Investment Limited Partnership (Mitsubishi UFJ Capital); Miyako Kyoto University Innovation No. 3 Investment Limited Partnership (Miyako Capital); Fujita TT Impact No. 1 Investment Limited Partnership (Fujita Innovation Capital / Tokai Tokyo Investment); NVCC No. 10 Investment Limited Partnership (Nippon Venture Capital Corporation); KUC No. 1 Investment Limited Partnership (Kobe University Capital); Aozora HYBRID No. 3 Investment Limited Partnership (Aozora Corporate Investment); The Joyo Bank, Ltd.
AI Semantic Keywords: United Immunity; Investments; Capital Financing; grant funding; Japan Agency for Medical Research and Development (AMED); Strengthening Program for Pharmaceutical Startup Ecosystem (V-eco); ¥5.0 billion; UI-102; in vivo CAR-Macrophage Therapy; in vivo CAR-macrophage immunotherapy; CAR-macrophage; macrophage engineering; solid tumors; Refractory Solid Tumors; fibrotic diseases; clinical stage biotechnology company; global clinical development; therapeutic areas; oncology; in vivo immunotherapies; drug-discovery company; R&D capabilities; Masato Kishida
About United Immunity, Co., Ltd.
Unite the Power of Immunity and Nanoparticle, Change the Future of Patients
United Immunity is a clinical-stage biotechnology company pioneering next-generation in vivo cell therapies with its proprietary Myeloid Targeting Platform™, designed to selectively target and program macrophages and dendritic cells directly in patients. The platform comprises two complementary pullulan-based nanoparticle technologies: P-LNP, a PEG-free, pullulan-coated lipid nanoparticle for delivery of mRNA, siRNA, and DNA; and PNP, a pullulan nanoparticle for delivery of small molecules, peptides, and proteins. Both technologies enable selective delivery to DC-SIGN-expressing myeloid cells in diseased tissues and lymphoid organs, with potential applications across cancer, fibrosis, autoimmune diseases, and infectious disease vaccines.
The company’s lead program, UI-102, is in Phase 1/2 clinical development and uses PNP to encapsulate and deliver a TLR7/8 small-molecule agonist to tumor-associated macrophages, with the goal of transforming immunologically “cold” tumors into “hot,” immune-responsive tumors. The company also develops an in vivo CAR-macrophage (CAR-M) therapy designed to program macrophages directly in patients using P-LNP-delivered CAR-encoding mRNA for cancer treatment and an in vivo macrophage therapy designed to restore TIM4 expression using P-LNP technology for the treatment of fibrotic diseases, including MASH and IPF.
For more information, please visit www.unitedimmunity.co.jp/eng/
www.linkedin.com/company/unitedimmunitycoltd
Contact
United Immunity, Co., Ltd.
Masato Kishida, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
Source: Biotech Newswire